1. Home
  2. MNOV vs HEQ Comparison

MNOV vs HEQ Comparison

Compare MNOV & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$2.64

Market Cap

137.8M

Sector

Health Care

ML Signal

HOLD

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

HOLD

Current Price

$11.29

Market Cap

139.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNOV
HEQ
Founded
2000
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
137.8M
139.0M
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
MNOV
HEQ
Price
$2.64
$11.29
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
★ 683.6K
21.2K
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,360,807.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$180.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 194.15
N/A
52 Week Low
$1.17
$10.46
52 Week High
$3.90
$12.00

Technical Indicators

Market Signals
Indicator
MNOV
HEQ
Relative Strength Index (RSI) 62.19 38.98
Support Level $1.28 $11.27
Resistance Level $3.90 $11.63
Average True Range (ATR) 0.30 0.21
MACD 0.04 -0.03
Stochastic Oscillator 43.06 23.93

Price Performance

Historical Comparison
MNOV
HEQ

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: